An Open-Label Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in Study MYK-461-004 (PIONEER)
Latest Information Update: 11 Jan 2025
At a glance
- Drugs Mavacamten (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Adverse reactions
- Acronyms PIONEER-OLE
- Sponsors Bristol-Myers Squibb
- 31 Jan 2024 Status changed from active, no longer recruiting to completed.
- 06 Mar 2023 Updated Results for cardiac hemodynamics and biomarkers, symptoms and quality of life, presented at the 72nd Annual Scientific Session of the American College of Cardiology together with the World Heart Federation
- 27 Feb 2023 According to a Bristol-Myers Squibb media release, data from the study will be presented at the American College of Cardiology Annual Scientific Session Together With World Congress of Cardiology.